Horm Metab Res 2017; 49(12): 977-983
DOI: 10.1055/s-0043-119802
Review
© Georg Thieme Verlag KG Stuttgart · New York

Primary Aldosteronism: The Next Five Years

John W. Funder
1   Hudson Institute of Medical Research and Monash University, Clayton, Australia
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 06. August 2017

accepted 07. September 2017

Publikationsdatum:
24. Oktober 2017 (online)

Abstract

The management of primary aldosteronism is widely varied within various published guidelines, with very little in the way of data supporting the choice of one variation over others. Current estimates of prevalence are probably accurate for aldosterone producing adenoma, but fall very short of that for bilateral adrenal hyperplasia. Discovery at the level of basic science has proven illuminating over the past 6 years in terms of unilateral disease and both somatic and germline mutations, with much less focus on the much more common bilateral disease; Attempts at harmonization have begun – for example, criteria for complete/partial/absent cure after adrenalectomy for unilateral disease; again focus on bilateral disease is muted. A number of possibilities are suggested as agenda for active consideration and change, across a wide range of areas – referral patterns, screening, confirmation and lateralization, what will be needed is discussion and agreement, to fill the lacunae within the current guidelines. Those involved will want to change to make such an agenda possible.

 
  • References

  • 1 Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, Gabetti L, Mengozzi G, Williams TA, Rabbia F, Veglio F, Mulatero P. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol 2017; 69: 1811-1820
  • 2 Helber A, Wambach G, Hummerich W, Bönner G, Meurer KA, Kaufmann W. Evidence for a subgroup of essential hypertensives with non-suppressible excretion of aldosterone during sodium loading. Klin Wochenschr 1980; 58: 439-447
  • 3 Collins RD, Weinberger MH, Dowdy AJ, Nokes GW, Gonzales CM, Luetscher JA. Abnormally sustained aldosterone secretion during salt loading in patients with various forms of benign hypertension, relation to plasma renin activity. J Clin Invest 1970; 49: 1415
  • 4 Grim CE, Peters THJ. Low renin hypertension: a state of inappropriate secretion of aldosterone. J Lab Clin Med 1971; 78: 816
  • 5 Fournier A, Lagrue G, Baulon A, Nakache JP, Kazandjian M, Legrand JC, Menard J. Significance and prediction of spironolactone effectiveness in essential hypertension. In: Extrarenal activity of aldosterone and its antagonists. Excerpta Medica; Amsterdam 1972; 54
  • 6 Leutscher JA, Beckerhoff R, Dowdy AJ, Wilkinson R. Incomplete suppression of aldosterone secretion and plasma concentration n hypertensive patients on high sodium intake. In Genest Koiw W. (eds) Hypertension 72. Berlin: Springer; 1972: 286
  • 7 Klaus D, Klumpp F, Zehner J. Primary hypertension with low plasma renin level. Dtsch Med Wochenschr 1973; 42: 1980-1987
  • 8 Helber A, Meurer KA, Rosskamp E, Wambach G, Dickmans HA, Kaufmann W. Aldosterone excretion and plasma renin activity in patients with essential hypertension and with primary aldosteronism. Klin Wochenschr 1974; 52: 966-973
  • 9 Kloppenburg PWC, Drayer JIM, Benraad HB, Benraad ThJ. Normal aldosterone versus supranormal aldosterone hypertension: and alternative to normal renin versus low renin hypertension. In Distler W. (ed) Current Problems in Hypertension. Stuttgart: Thieme; 1974: 143
  • 10 Gouli A, Kaltsas G, Tzonou A, Markou A, Androulakis II, Ragkou D, Vamvakidis K, Zografos G, Kontogeorgos G, Chrousos GP, Piaditis G. High prevalence of autonomous aldosterone secretion among patients with essential hypertension. Eur J Clin Invest 2011; 41: 1227-1236
  • 11 Markou A, Sertedaki A, Kaltsas G, Androulakis II, Marakaki C, Pappa T, Gouli A, Papanastasiou L, Fountoulakis S, Zacharoulis A, Karavidas A, Ragkou D, Charmandari E, Chrousos GP, Piaditis GP. Stress-induced aldosterone hyper-secretion in a substantial subset of patients with essential hypertension. J Clin Endocrinol Metab 2015; 100: 2857-2864
  • 12 Stowasser M, Sharman J, Leano R, Gordon RD, Ward G, Cowley D, Marwick TH. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab 2005; 90: 5070-5076
  • 13 Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, Benjamin EJ, Levy D. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351: 33-41
  • 14 Ito Y, Takeda R, Karashima S, Yamamoto Y, Yoneda T, Takeda Y. Prevalence of primary aldosteronism among prehypertensive and stage 1 hypertensive subjects. Hypertens Res 2011; 34: 98-102
  • 15 Markou A, Pappa T, Kaltsas G, Gouli A, Mitsakis K, Tsounas P, Prevoli A, Tsiavos V, Papanastasiou L, Zografos G, Chrousos GP, Piaditis GP. Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: a very high odds ratio for progression into arterial hypertension. J Clin Endocrinol Metab 2013; 98: 1409-1416
  • 16 Baudrand R, Guarda FJ, Fardella C, Hundemer G, Brown J, Williams G, Vaidya A. Continuum of renin-independent aldosteronism in normotension. Hypertension 2017; 69: 950-956
  • 17 Ori Y, Chagnac A, Korzets A, Zingerman B, Herman-Edelstein M, Bergman M, Gafter U, Salman H. Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone. Nephrol Dial Transplant 2013; 1-5
  • 18 Nanba K, Vaidya A, Williams GH, Zheng I, Else T, Rainey WE. Age-related autonomous aldosteronism. Circulation 2017; 136: 347-355
  • 19 Nishimoto K, Tomlins SA, Kuick R, Cani AK, Giordano TJ, Hovelson DH, Liu CJ, Sanjanwala AR, Edwards MA, Gomez-Sanchez CE, Nanba K, Rainey WE. Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands. Proc Natl Acad Sci USA 2015; 112: E4591-E4599
  • 20 Wisgerhof M, Brown RD. Increased adrenal sensitivity to angiotensin II in low renin essential hypertension. J Clin Invest 1978; 61: 1456-1462
  • 21 Carey RM, Ayers CR, Vaughan Jr. ED, Peach MJ, Herf SM. Activity of [des-aspartyI1]-angiotensin II in primary aldosteronism. J Clin Invest 1979; 69: 718-726
  • 22 Wisgerhof M, Brown RD, Hogan MJ, Carpenter PC, Edis AJ. The plasma aldosterone response to angiotensin II infusion in aldosterone-producing adenoma and idiopathic hyperaldosteronism. J Clin Endocrinol Metab 1981; 52: 195-198
  • 23 Gordon RD, Gomez-Sanchez CE, Hamlet SM, Tunny TJ, Klemm SA. Angiotensin-responsive aldosterone-producing adenoma masquerades as idiopathic hyperaldosteronism (IHA: adrenal hyperplasia) or low-renin essential hypertension. J Hypertens Suppl 1987; 5: S103-S106
  • 24 Rossi GP, Funder JW. Adrenal Venous sampling versus computed tomographic scan to determine treatment in primary aldosteronism (The SPARTACUS Trial): A critique. Hypertension 2017; 3: 396-397
  • 25 Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Young Jr WF. The management of primary aldosteronism: case detection diagnosis and treatment: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016; 101: 1889-1916
  • 26 Ahmed AH, Cowley D, Wolley M, Gordon RD, Xu S, Taylor PJ, Stowasser M. Seated saline suppression testing for the diagnosis of primary aldosteronism: a preliminary study. J Clin Endocrinol Metab 2014; 99: 2745-2753
  • 27 Williams TA, Lenders J, Mulatero P, Burrello J, Rottenkolber M, Adolf C, Fumitoshi S, Amar L, Quinkler M, Deinum J, Beuschlein F, Kitamoto KK, Pham U, Morimoto R, Umakoshi H, Prejbisz A, Kocjan T, Naruse M, Stowasser M, Nishikawa T, Young Jr. WF, Gomez-Sanchez CE, Funder JW, Reincke M. Outcomes after adrenalectomy for unilateral primary aldosteronism: an International consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol 2017; 5: 689-699
  • 28 Kassahn KS, Ragan MA, Funder JW. Mineralocorticoid receptors: evolutionary and pathophysiological considerations. Endocrinology 2011; 152: 1883-1890
  • 29 Mihailidou AS, Loan Le TY, Mardini M, Funder JW. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 2009; 54: 1306-1312
  • 30 Levy DG, Rocha R, Funder JW. Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab 2004; 89: 2736-2740
  • 31 Young M, Funder JW. Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats. Endocrinology 2004; 145: 3153-3157
  • 32 Mulatero P, Monticone S, Burrello J, Veglio F, Williams TA, Funder J. Guidelines for primary aldosteronism: uptake by primary care physicians in Europe. J Hypertens 2016; 34: 2253-2257
  • 33 Choi M, Scholl UI, Yue P, Björkland P, Zhao B, Nelson-Williams C, Ji W, Cho Y, Patel A, Men CJ, Lolis E, Wisgerhof MV, Geller DS, Mane S, Hellman P, Westin G, Åkerström G, Wang W, Carling T, Lifton RP. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011; 331: 768-772
  • 34 Boulkroun S, Beuschlein F, Rossi GP, Golib-Dzib JF, Fischer E, Amar L, Mulatero P, Samson-Couterie B, Hahner S, Quinkler M, Fallo F, Letizia C, Allolio B, Ceolotto G, Cicala MV, Lang K, Lefebvre H, Lenzini L, Maniero C, Monticone S, Perrocheau M, Pilon C, Plouin PF, Rayes N, Seccia TM, Veglio F, Williams TA, Zinnamosca L, Mantero F, Benecke A, Jeunemaitre X, Reincke M, Zennaro MC. Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension 2012; 59: 592-598
  • 35 Machiavelli The Prince. 1513